Literature DB >> 19760538

The clinical approach to lung disease in patients with cystic fibrosis.

Brian P O'Sullivan1, Patrick Flume.   

Abstract

There is strong evidence that early, aggressive therapy of lung disease leads to improved quality and quantity of life for patients with cystic fibrosis (CF). The treatment of pulmonary disease associated with CF is multifactorial, encompassing prophylaxis, aggressive treatment of infection, use of antiinflammatory agents, and treatment of severe complications. Chest physiotherapy on a regular basis, perhaps using new modalities that allow patient autonomy, is also crucial. This review covers the pathogenesis of CF lung disease and current approaches to therapy, highlighting guidelines recently published by the Cystic Fibrosis Foundation. Clinicians caring for patients with CF should maximize current therapies with the goal of preserving lung function until the time a more definitive curative or controller medication is developed. Empowering patients in the process of providing their own care is a key to achieving this goal. Copyright Thieme Medical Publishers.

Entities:  

Mesh:

Year:  2009        PMID: 19760538     DOI: 10.1055/s-0029-1238909

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  12 in total

1.  Evaluation and management of pulmonary disease in ataxia-telangiectasia.

Authors:  Sharon A McGrath-Morrow; W Adam Gower; Cynthia Rothblum-Oviatt; Alan S Brody; Claire Langston; Leland L Fan; Maureen A Lefton-Greif; Thomas O Crawford; Michelle Troche; John T Sandlund; Paul G Auwaerter; Blaine Easley; Gerald M Loughlin; John L Carroll; Howard M Lederman
Journal:  Pediatr Pulmonol       Date:  2010-09

2.  Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.

Authors:  Elena K Schneider; Felisa Reyes-Ortega; John W Wilson; Tom Kotsimbos; Dominic Keating; Jian Li; Tony Velkov
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-10-24       Impact factor: 3.205

3.  Metabolomic Description of Ivacaftor Elevating Polymyxin B Mediated Antibacterial Activity in Cystic Fibrosis Pseudomonas aeruginosa.

Authors:  Rafah Allobawi; Drishti P Ghelani; Elena K Schneider-Futschik
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-27

Review 4.  Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?

Authors:  E K Schneider; F Reyes-Ortega; J Li; T Velkov
Journal:  Clin Pharmacol Ther       Date:  2016-11-23       Impact factor: 6.875

5.  Vitamin d deficiency in cystic fibrosis.

Authors:  William B Hall; Amy A Sparks; Robert M Aris
Journal:  Int J Endocrinol       Date:  2010-01-28       Impact factor: 3.257

6.  Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients.

Authors:  Elena K Schneider; Felisa Reyes-Ortega; Jian Li; Tony Velkov
Journal:  J Vis Exp       Date:  2017-10-15       Impact factor: 1.355

Review 7.  Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function.

Authors:  Emer P Reeves; Cormac McCarthy; Oliver J McElvaney; Maya Sakthi N Vijayan; Michelle M White; Danielle M Dunlea; Kerstin Pohl; Noreen Lacey; Noel G McElvaney
Journal:  World J Crit Care Med       Date:  2015-08-04

Review 8.  Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis.

Authors:  Elena K Schneider-Futschik
Journal:  Gene Ther       Date:  2019-07-12       Impact factor: 5.250

Review 9.  Hypertonic saline in treatment of pulmonary disease in cystic fibrosis.

Authors:  Emer P Reeves; Kevin Molloy; Kerstin Pohl; Noel G McElvaney
Journal:  ScientificWorldJournal       Date:  2012-05-03

10.  Investigation of aminoglycoside resistance inducing conditions and a putative AmrAB-OprM efflux system in Burkholderia vietnamiensis.

Authors:  Agatha N Jassem; Connor M Forbes; David P Speert
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-01-06       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.